WEKO3
アイテム
{"_buckets": {"deposit": "725214d7-b619-4b27-837c-8e22da999225"}, "_deposit": {"created_by": 1, "id": "75677", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "75677"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00075677", "sets": ["1"]}, "author_link": ["908021", "908024", "908027", "908018", "908019", "908022", "908025", "908026", "908028", "908020", "908023"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "5", "bibliographicPageEnd": "1664", "bibliographicPageStart": "1653", "bibliographicVolumeNumber": "110", "bibliographic_titles": [{"bibliographic_title": "Cancer Science"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is highly expressed in malignant mesothelioma. The rat-human chimeric antibody NZ-12 has high affinity for human podoplanin and antibody-dependent cellular cytotoxicity, and is applicable for radioimmunotherapy (RIT) to enhance the antitumor effect. In the present study, we evaluated the in vivo and in vitro properties of radiolabeled NZ-12 and the antitumor effect of RIT with Y-labeled NZ-12 in an NCI-H226 (H226) malignant mesothelioma xenograft mouse model. In-labeled NZ-12 bound specifically to H226 cells with high affinity, and accumulation was high in H226 tumors but low in major organs. RIT with Y-labeled NZ-12 significantly suppressed tumor growth and prolonged survival without body weight loss and obvious adverse effects. Higher podoplanin expression levels were observed in human mesothelioma specimens, suggesting higher tumor accumulation of Y-labeled NZ-12 in patients compared with the H226 tumor xenografts. Our findings suggest that Y-labeled NZ-12 is a promising RIT agent as a new therapeutic option for malignant mesothelioma that warrants further clinical studies to evaluate the dosimetry and efficacy in patients. This article is protected by copyright. All rights reserved.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本癌学会"}]}, "item_8_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "30801908", "subitem_relation_type_select": "PMID"}}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1111/cas.13979", "subitem_relation_type_select": "DOI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1349-7006", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Sudo, Hitomi"}], "nameIdentifiers": [{"nameIdentifier": "908018", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "908019", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugyo, Aya"}], "nameIdentifiers": [{"nameIdentifier": "908020", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saga, Tsuneo"}], "nameIdentifiers": [{"nameIdentifier": "908021", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "K Kaneko, Mika"}], "nameIdentifiers": [{"nameIdentifier": "908022", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kato, Yukinari"}], "nameIdentifiers": [{"nameIdentifier": "908023", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Higashi, Tatsuya"}], "nameIdentifiers": [{"nameIdentifier": "908024", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sudo, Hitomi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "908025", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Atsushi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "908026", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugyo, Aya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "908027", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Higashi, Tatsuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "908028", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/75677", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-03-01"}, "publish_date": "2019-03-01", "publish_status": "0", "recid": "75677", "relation": {}, "relation_version_is_last": true, "title": ["Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma"], "weko_shared_id": -1}
Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma
https://repo.qst.go.jp/records/75677
https://repo.qst.go.jp/records/7567739e0d0e2-29aa-4a14-84e1-e6405362f641
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-03-01 | |||||
タイトル | ||||||
タイトル | Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Sudo, Hitomi
× Sudo, Hitomi× Tsuji, Atsushi× Sugyo, Aya× Saga, Tsuneo× K Kaneko, Mika× Kato, Yukinari× Higashi, Tatsuya× Sudo, Hitomi× Tsuji, Atsushi× Sugyo, Aya× Higashi, Tatsuya |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is highly expressed in malignant mesothelioma. The rat-human chimeric antibody NZ-12 has high affinity for human podoplanin and antibody-dependent cellular cytotoxicity, and is applicable for radioimmunotherapy (RIT) to enhance the antitumor effect. In the present study, we evaluated the in vivo and in vitro properties of radiolabeled NZ-12 and the antitumor effect of RIT with Y-labeled NZ-12 in an NCI-H226 (H226) malignant mesothelioma xenograft mouse model. In-labeled NZ-12 bound specifically to H226 cells with high affinity, and accumulation was high in H226 tumors but low in major organs. RIT with Y-labeled NZ-12 significantly suppressed tumor growth and prolonged survival without body weight loss and obvious adverse effects. Higher podoplanin expression levels were observed in human mesothelioma specimens, suggesting higher tumor accumulation of Y-labeled NZ-12 in patients compared with the H226 tumor xenografts. Our findings suggest that Y-labeled NZ-12 is a promising RIT agent as a new therapeutic option for malignant mesothelioma that warrants further clinical studies to evaluate the dosimetry and efficacy in patients. This article is protected by copyright. All rights reserved. | |||||
書誌情報 |
Cancer Science 巻 110, 号 5, p. 1653-1664, 発行日 2019-02 |
|||||
出版者 | ||||||
出版者 | 日本癌学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1349-7006 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 30801908 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1111/cas.13979 |